KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to 31.35%.

  • Supernus Pharmaceuticals' EBITDA Margin fell 546000.0% to 31.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.42%, marking a year-over-year decrease of 145100.0%. This contributed to the annual value of 12.34% for FY2024, which is 132100.0% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported EBITDA Margin of 31.35% as of Q3 2025, which was down 546000.0% from 7.34% recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year EBITDA Margin high stood at 24.14% for Q2 2021, and its period low was 31.35% during Q3 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median EBITDA Margin value was 5.29% (recorded in 2023), while the average stood at 5.19%.
  • In the last 5 years, Supernus Pharmaceuticals' EBITDA Margin soared by 263800bps in 2024 and then crashed by -546000bps in 2025.
  • Supernus Pharmaceuticals' EBITDA Margin (Quarter) stood at 3.83% in 2021, then soared by 435bps to 20.52% in 2022, then plummeted by -103bps to 0.61% in 2023, then skyrocketed by 2128bps to 12.29% in 2024, then tumbled by -355bps to 31.35% in 2025.
  • Its last three reported values are 31.35% in Q3 2025, 7.34% for Q2 2025, and 6.85% during Q1 2025.